PT  - JOURNAL ARTICLE
AU  - Ando, Hajime
AU  - Ikegami, Kazunori
AU  - Nagata, Tomohisa
AU  - Tateishi, Seiichiro
AU  - Eguchi, Hisashi
AU  - Tsuji, Mayumi
AU  - Matsuda, Shinya
AU  - Fujino, Yoshihisa
AU  - Ogami, Akira
AU  - ,
TI  - Effect of commuting on the risk of COVID-19 and COVID-19-induced anxiety
AID  - 10.1101/2021.05.01.21256090
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.05.01.21256090
4099  - http://medrxiv.org/content/early/2021/05/05/2021.05.01.21256090.short
4100  - http://medrxiv.org/content/early/2021/05/05/2021.05.01.21256090.full
AB  - Background To prevent the spread of coronavirus disease (COVID-19), it is important to avoid 3Cs (closed spaces, crowded places, and close-contact settings). However, the risk of contact with an unspecified number of people is inevitable while commuting to and from work. In this study, we investigated the relationship between commuting, and the risk of COVID-19 and COVID-19-induced anxiety.Methods An internet-based questionnaire survey was conducted to obtain a dataset from 27036 respondents. One-way commuting time was evaluated using a five-case method. The commuting distance was estimated using zip codes of the home and workplace. Logistic regression analysis was performed with the following outcomes: COVID-19 risk, close contact, infection anxiety, and infection anxiety due to commuting. Commuting distance and commuting time were analyzed separately in the model. We excluded participants with incalculable commuting distance, commuting distance exceeding 300 km, commuting distance of 0 km, or who telecommuted at least once a week.Results The total number of participants included in the analysis was 14038. The adjusted odds ratios (aORs) of using public transportation for severe acute respiratory syndrome coronavirus 2 infection were 4.17 (95% confidence interval [CI]: 2.51-6.93) (commuting time) and 5.18 (95% CI: 3.06-8.78) (commuting distance). The aOR of COVID-19 diagnosis decreased significantly with increasing commuting distance. The aORs of using public transportation to infection anxiety were 1.44 (95% CI: 1.31-1.59) (commuting time) and 1.45 (95% CI: 1.32-1.60) (commuting distance). The longer the commuting time, the more the aOR increased..Conclusions COVID-19 risk, close contact, and infection anxiety were all associated with the use of public transportation during commuting. Both commuting distance and time were associated with infection anxiety due to commuting, and the strength of the association increased with increase in commuting time distance. Since transportation by commuting is associated with COVID-19 risk and anxiety, we recommend the use of telecommuting and other means of work.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported and partly funded by the University of Occupational and Environmental Health, Japan; General Incorporated Foundation (Anshin Zaidan); The Development of Educational Materials on Mental Health Measures for Managers at Small-sized Enterprises; Health, Labour and Welfare Sciences Research Grants; Comprehensive Research for Women's Healthcare (H30-josei-ippan-002); Research for the Establishment of an Occupational Health System in Times of Disaster (H30-roudou-ippan-007), scholarship donations from Chugai Pharmaceutical Co., Ltd., the Collabo-Health Study Group, and Hitachi Systems, Ltd.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Committee of the University of Occupational and Environmental Health, Japan;reference (No. R2-079). The survey was conducted after an online confirmation of the participants' consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are not available due to ethical restrictions.aORadjusted odds ratioCIconfidence intervalCOVID-19coronavirus disease 2019MLITMinistry of Land, Infrastructure, Transport, and TourismSARS-CoV-2severe acute respiratory syndrome coronavirus 2